Cargando…

Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function

Peficitinib (ASP015K) is a novel Janus kinase inhibitor developed for the treatment of rheumatoid arthritis (RA). The impact of hepatic impairment on the peficitinib pharmacokinetic (PK) and safety profile was investigated in non‐RA subjects (n = 24) in an open‐label, parallel‐group, multicenter com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miyatake, Daisuke, Shibata, Tomohisa, Toyoshima, Junko, Kaneko, Yuichiro, Oda, Kazuo, Nishimura, Tetsuya, Katashima, Masataka, Sakaki, Masashi, Inoue, Kazuaki, Ito, Takayoshi, Uchida, Naoki, Furihata, Kenichi, Urae, Akinori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496893/ https://www.ncbi.nlm.nih.gov/pubmed/31833184 http://dx.doi.org/10.1002/cpdd.751

Ejemplares similares

Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function
por: Miyatake, Daisuke, et al.
Publicado: (2019)

Pharmacokinetics, Pharmacodynamics, and Safety of Peficitinib (ASP015K) in Healthy Male Caucasian and Japanese Subjects
por: Shibata, Mai, et al.
Publicado: (2020)

The Bioequivalence of Two Peficitinib Formulations, and the Effect of Food on the Pharmacokinetics of Peficitinib: Two‐Way Crossover Studies of a Single Dose of 150 mg Peficitinib in Healthy Volunteers
por: Shibata, Mai, et al.
Publicado: (2020)

Pharmacokinetics and Safety of Single and Multiple Doses of Peficitinib (ASP015K) in Healthy Chinese Subjects
por: Gao, Xin, et al.
Publicado: (2022)

A drug–drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers
por: Shibata, Mai, et al.
Publicado: (2020)

Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis
por: Toyoshima, Junko, et al.
Publicado: (2020)

Exposure–response modeling of peficitinib efficacy in patients with rheumatoid arthritis
por: Toyoshima, Junko, et al.
Publicado: (2021)

Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan
por: Takeuchi, Tsutomu, et al.
Publicado: (2021)

Investigation of Potential Drug–Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis
por: Zhu, Tong, et al.
Publicado: (2020)

Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
por: Takeuchi, Tsutomu, et al.
Publicado: (2020)

Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
por: Takeuchi, Tsutomu, et al.
Publicado: (2020)

Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
por: Takeuchi, Tsutomu, et al.
Publicado: (2016)

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan
por: Takeuchi, Tsutomu, et al.
Publicado: (2019)

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)
por: Tanaka, Yoshiya, et al.
Publicado: (2019)

Evaluation of Food and Spherical Carbon Adsorbent Effects on the Pharmacokinetics of Roxadustat in Healthy Nonelderly Adult Male Japanese Subjects
por: Shibata, Tomohisa, et al.
Publicado: (2018)

Efficacy of peficitinib in two patients with rheumatoid arthritis on maintenance hemodialysis
por: Nishimura, Akito, et al.
Publicado: (2022)

Targeting Activated Synovial Fibroblasts in Rheumatoid Arthritis by Peficitinib
por: Diller, Magnus, et al.
Publicado: (2019)

Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults
por: Kusawake, Tomohiro, et al.
Publicado: (2017)

Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment
por: Kumagai, Yuji, et al.
Publicado: (2019)

In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors
por: Kitanaga, Yukihiro, et al.
Publicado: (2020)

Peficitinib Inhibits the Chemotactic Activity of Monocytes via Proinflammatory Cytokine Production in Rheumatoid Arthritis Fibroblast-Like Synoviocytes
por: Ikari, Yuzo, et al.
Publicado: (2019)

Successful peficitinib addition on anti-MDA5 antibody-positive dermatomyositis refractory to triple therapy and glucocorticoid reduction
por: Oba, Yuki, et al.
Publicado: (2022)

Antibacterial mechanism of the Asp-Asp-Asp-Tyr peptide
por: Zhuang, Shanshan, et al.
Publicado: (2022)

The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies
por: Kusawake, Tomohiro, et al.
Publicado: (2017)

Jumping from ASP to ASP.NET
por: Parsons, Doug
Publicado: (2008)

Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study
por: Genovese, Mark C., et al.
Publicado: (2019)

Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

ASP
por: Berardi, Nick, et al.
Publicado: (2009)

ASP
por: Varallo, Vincent
Publicado: (2009)

ASP
por: Love, Chris
Publicado: (2009)

ODP015 "Malignant" Hypertension in an Older Male
por: Naha, Sowjanya, et al.
Publicado: (2022)

Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment
por: Aoyama, Yumiko, et al.
Publicado: (2012)

Population pharmacokinetic modeling of Sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma
por: Aoyama, Yumiko, et al.
Publicado: (2012)

DRAFT ATLAS ATRECON manual (Version 0.015)
por: Offline Software Group
Publicado: (1994)

The ATLAS Level-1 Central Trigger System 015
por: Borrego-Amaral, P, et al.
Publicado: (2004)

Optimization of the Fermentation Process of Actinomycete Strain Hhs.015(T)
por: Wang, Xinxuan, et al.
Publicado: (2010)

AB015. How to do the combined ureteroscope well
por: Zhang, Ming
Publicado: (2018)

Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study
por: Ono, Akira, et al.
Publicado: (2020)

Professional ASP
por: Sanford, Jacob J
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_6q7c66psjrkds0rdhg135vgsvc